Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology

Autor: Zhishu Tang, Kunxia Hu, Yunlan Wang, Zhisheng Wu, Xiao Song, Lizhu Han, Jing Kou
Rok vydání: 2021
Předmět:
Male
Drug
animal structures
media_common.quotation_subject
Pharmaceutical Science
Traditional Chinese medicine
Pharmacology
medicine.disease_cause
030226 pharmacology & pharmacy
01 natural sciences
Signal pathway
Rats
Sprague-Dawley
Food and drug administration
03 medical and health sciences
0302 clinical medicine
Network pharmacology
Drug Discovery
medicine
Animals
pneumonia
media_common
Inflammation
signal pathway
Tumor Necrosis Factor-alpha
Streptococcus
business.industry
lcsh:RM1-950
NF-kappa B
General Medicine
Pneumonia
Pneumococcal
medicine.disease
Rats
0104 chemical sciences
Disease Models
Animal
010404 medicinal & biomolecular chemistry
Pneumonia
Streptococcus pneumoniae
lcsh:Therapeutics. Pharmacology
Complementary and alternative medicine
traditional chinese medicine
Molecular Medicine
business
Research Article
Drugs
Chinese Herbal
Signal Transduction
Zdroj: Pharmaceutical Biology, Vol 59, Iss 1, Pp 209-221 (2021)
Pharmaceutical Biology
article-version (VoR) Version of Record
ISSN: 1744-5116
1388-0209
Popis: Context Re-yan-ning mixture (RYNM) is a new national drug approved by China's State Food and Drug Administration for the treatment of colds, simple pneumonia and acute bronchitis. Objective To determine the mechanism of action of RYNM in the treatment of bacterial pneumonia. Materials and methods Using the network pharmacology approach, the multiple components, component candidate targets and multiple therapeutic targets of RYNM were screened and functionally enriched. Also, we established a rat Streptococcus pneumonia model to verify the results of network pharmacology enrichment analysis. Forty male SPF Sprague Dawley rats were divided into four groups of 10 rats: control (normal saline), model (normal saline), levofloxacin-intervened and RYNM-intervened groups. IL-10, NOS2, COX-1, IL-6, TNF-α and NF-κB in serum and BALF were detected by ELISA. Western blot detected IL-17, IL-6, TNF-α, COX-2 and Bcl-2. Results The network pharmacology approach successfully identified 48 bioactive components in RYNM, and 65 potential targets and 138 signal pathways involved in the treatment of Streptococcus pneumonia with RYNM. The in vivo experiments indicated that model group has visible inflammation and lesions while RYNM and levofloxacin groups have not. The RYNM exhibited its therapeutic effects on Streptococcus pneumonia mainly via the regulation of cell proliferation and survival through the IL-6/IL-10/IL-17, Bax/Bcl-2, COX-1/COX-2, NF-κB and TNF-α signalling pathways. Discussion and conclusions The present study demonstrated the protective effects of RYNM on Streptococcus pneumonia, providing a potential mechanism for the treatment of bacterial pneumonia with RYNM.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje